Achillion loses a lot after saying little

Shares of HCV play Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) dropped $1.89 (16%) to $10.23 after the company released 3Q14 earnings with no updates for two highly anticipated clinical studies of its HCV compounds ACH-3422 and ACH-3102, and without conducting a conference call.

Investors have been anticipating data from a Phase I trial of ACH-3422, an HCV NS5B uridine nucleotide polymerase inhibitor, in advance of the start of a Phase IIa trial next year. The future study will combine ACH-3422 with ACH-3102, a pan-genotypic second-generation HCV NS5A protein inhibitor. ...